Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants

  title={Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants},
  author={Felix M{\"u}ller and Elias Kraus and Friederike Holze and Anna M. Becker and Laura Ley and Yasmin Schmid and Patrick Vizeli and Matthias E. Liechti and Stefan J. Borgwardt},
  pages={1933 - 1943}
LSD and psilocybin are increasingly used in phase I trials and evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring drug-like experiences after the acute substance effects have worn off was described for both substances and especially attributed to LSD. According to the DSM-V, the persisting and distressing manifestation of these experiences is called hallucinogen-persisting perception disorder (HPPD). Data on both conditions is very limited. This study aims to… 

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

AEs are poorly defined in the context of psychedelic treatments and are probably underreported in the literature due to study design (lack of systematic assessment of AEs) and sample selection.

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?

Classic psychedelics are a loosely grouped class of drugs that activate serotonin 5HT2A receptors to induce complex behavioral, psychological, and physiological effects [1]; 5HT2A agonism induces the

Motives for the use of serotonergic psychedelics: A systematic review.

ISSUES Serotonergic psychedelics (SP) are psychoactive substances that produce unique sets of subjective effects, such as hallucinatory experiences. This systematic review is the first to summarise

Towards an understanding of psychedelic-induced neuroplasticity

Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly, clinical improvements can last

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder

There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder and psilocybin remains an experimental option that is only available through clinical trials or the special access program.

Psychedelics: Old trips, new destinations in psychopharmacology research

There is growing interest in the use of psychedelics as potential treatments for a variety of neuropsychiatric disorders.



Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.

A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.

Results of the survey suggest that HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances.

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Investigation of the acute autonomic, subjective, and endocrine effects of single doses of LSD, MDMA, and d-amphetamine in 28 healthy subjects indicates clearly distinct acute effects and may assist the dose-finding in substance-assisted psychotherapy research.

Flashbacks and HPPD: A Clinical-oriented Concise Review.

A clinical-oriented, comprehensive and concise review to treating psychiatrists of Hallucinogen Persisting Perception Disorder, which appears to be part of a broad spectrum of non-psychopathological and psychopathological states reported by hallucinogen users.

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects

Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects ofpsilocyin compared with placebo pretreatment.

Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?

Three articles rise the fundamental question of mechanism behind therapeutic effects of hallucinogenic and entactogenic substances, which patients might benefit from these treatments and which might not, how therapeutic effects can be promoted and risks further minimized.

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects

The LSD dose–response curve showed a ceiling effect for subjective good effects, and ego dissolution and anxiety increased further at a dose above 100 µg, which may assist with dose finding for future LSD research.

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

A critical mini review on psychopathological bases, etiological hypothesis, and psychopharmacological approaches toward HPPD, including the association with some novel substances, are provided here, by means of a literature search on PubMed/Medline, Google Scholar, and Scopus databases without time restrictions.

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

The aims of the present study are to review all the original studies about HPPD in order to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.